Turn Therapeutics (NASDAQ:TTRX) Upgraded to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Turn Therapeutics (NASDAQ:TTRX) from a sell rating to a hold rating in a research report report published on Saturday,Wall Street Zen reports.

Other research analysts have also issued research reports about the stock. Weiss Ratings lowered shares of Turn Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 18th. LADENBURG THALM/SH SH upgraded shares of Turn Therapeutics to a “strong-buy” rating in a research report on Monday, July 20th. WBB Securities reissued a “sell” rating and set a $10.00 target price on shares of Turn Therapeutics in a research note on Monday, September 14th. Zacks Research upgraded shares of Turn Therapeutics to a “hold” rating in a report on Tuesday, July 21st. Finally, Lucid Cap Mkts raised shares of Turn Therapeutics to a “strong-buy” rating in a research report on Thursday, September 24th. Two investment analysts have rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and two have given a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.00.

Turn Therapeutics Trading Up 5.4%

NASDAQ TTRX opened at $12.00 on Friday. The firm has a market capitalization of $357.48 million and a PE ratio of -41.38. The business’s 50-day moving average price is $11.46 and its two-hundred day moving average price is $7.63. The company has a current ratio of 1.19, a quick ratio of 1.19 and a debt-to-equity ratio of 8.83. Turn Therapeutics has a 12 month low of $2.57 and a 12 month high of $16.45.

Turn Therapeutics (NASDAQ:TTRX) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter. On average, analysts expect that Turn Therapeutics will post -0.40 EPS for the current year.

Institutional Trading of Turn Therapeutics

Large investors have recently modified their holdings of the stock. Tamar Securities LLC acquired a new position in shares of Turn Therapeutics during the 4th quarter valued at $59,000. Bank of America Corp DE bought a new position in Turn Therapeutics during the second quarter worth $103,000. Jefferies Financial Group Inc. acquired a new stake in Turn Therapeutics in the second quarter worth $119,000. DDFG Inc increased its stake in Turn Therapeutics by 34.9% in the first quarter. DDFG Inc now owns 70,534 shares of the company’s stock valued at $226,000 after purchasing an additional 18,246 shares in the last quarter. Finally, Bridgewater Advisors Inc. bought a new stake in Turn Therapeutics in the second quarter valued at $242,000.

Turn Therapeutics Company Profile

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.